Table 1.
Adverse effects of ezogabine reported in at least 5% of patients with intractable partial seizures in placebo-controlled add-on clinical trials
| Placebo, n = 427 (%) | Ezogabine 600 mg/d, n = 281 (%) | Ezogabine 900 mg/d, n = 273 (%) | Ezogabine 1200 mg/d, n = 259 (%) | |
|---|---|---|---|---|
| Dizziness | 38 (8.9) | 41 (14.6) | 64 (23.4) | 84 (32.4) |
| Somnolence | 51 (11.9) | 43 (15.3) | 67 (24.5) | 69 (26.6) |
| Confusion | 11 (2.6) | 12 (4.3) | 21 (7.7) | 42 (16.2) |
| Headache | 68 (15.9) | 34 (12.1) | 47 (17.2) | 39 (15.1) |
| Fatigue | 25 (5.9) | 45 (16) | 40 (14.7) | 34 (13.1) |
| Coordination disturbance | 12 (2.8) | 14 (5) | 14 (5.1) | 30 (11.6) |
| Blurred vision | 9 (2.1) | 5 (1.8) | 12 (4.4) | 27 (10.4) |
| Memory impairment | 11 (2.6) | 7 (2.5) | 15 (5.5) | 24 (9.3) |
| Vertigo | 9 (2.1) | 22 (7.8) | 21 (7.7) | 24 (9.3) |
| Nausea | 22 (5.2) | 18 (6.4) | 17 (6.2) | 22 (8.5) |
| Attention disturbance | 4 (<1) | 17 (6) | 15 (5.5) | 17 (6.6) |
| Urinary/renal | 55 (12.9) | 38 (13.5) | 35 (12.8) | 65 (25.1) |
| Discontinued due to adverse events | 39 (9.1) | 41 (14.6) | 65 (23.8) | 73 (28.2) |
| Death | 3 | 1 | 0 | 1 |
Adapted from Epilepsy Res. Porter et al; Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials. © 2012, with permission from Elsevier.36